Go Back
Karyopharm Therapeutics Inc. reports $34.1 million Q1 loss
By USInMinutes - May 04, 2023, 10:25 AM ET
Last Updated - Jul 18, 2023, 03:40 PM EDT
The company generated $38.70 million in quarterly revenue
Karyopharm Therapeutics Inc. [KPTI] has reported fiscal Q1 loss of $34.10 million.
On a per-share basis, the DE based company said its diluted earnings are $0.30.
The Pharmaceutical Preparations firm posted revenue of $38.70 million in this period.
Also Read:
- Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDS
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Karyopharm to Report First Quarter 2023 Financial Results on May 4, 2023
- Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at AACR 2023
- Karyopharm To Present Data from Phase 1 Study of Selinexor in Patients with Treatment-Naïve Myelofibrosis at AACR and to Host Investor Webcast on April 18th
NewsInMinutes is an offering of 10kInfo, Inc., bringing you news on the latest regulatory filings. You may subscribe to news alerts here.
Sponsored
Sponsored
Read More from Investing
Popular News
Latest News
